RT Conference Proceedings
T1 BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
A1 Schmid, P.
A1 Salvador Bofill, J.
A1 Bermejo, B.
A1 Phillips, M.
A1 Wheatley, D.
A1 Neus, F.
A1 Schem, C.
A1 Stradella, A.
A1 Mele, M.
A1 Cortes Salgado, A.
A1 Quiroga, V.
A1 Anton Torres, A.
A1 Llombart Cussac, A.
A1 Zamora, E.
A1 Viale, G.
A1 Kuemmel, S.
A1 Prendergast, A.
A1 Mousa, K.
A1 Gluz, O.
A1 Cortes, J.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/27174
UL https://hdl.handle.net/10668/27174
LA en
DS RISalud
RD Apr 12, 2025